Alpha Stem Cell Clinics Trials

The Alpha Stem Cell Clinics Network is pursuing its goal to accelerate the development and delivery of stem cell treatments to patients through high quality clinical trials. 

Browse the list of ongoing trials at Alpha Stem Cell Clinic locations in the table below. You can sort trials based on different fields by clicking on the appropriate column header. Trials are automatically listed by status of trial enrollment and Alpha Clinic location.

Alpha Clinic Trials

Alpha ClinicAlpha Clinic ContactTrial SponsorDisease IndicationClinical Trial NameStatus of EnrollmentLearn More
UCSF & UC Davis
Hanjing Zhou
415-502-7434
hanging.zhou@ucsf.edu
COVID-19/ARDS Mesenchymal Stromal Cells for ARDS (COVID positive and COVID negative) Recruiting
City of Hope
Hormoz Babaei Mirshkarlo
626-218-8074
hmirshkarlo@coh.org
Adaptimmune Cancer - Myeloma NY-ESO-1ᶜ²⁵⁹T Alone and in Combination With Pembrolizumab for Multiple Myeloma Recruiting
City of Hope
Warren Chow, MD
(626) 256-4673 x89200
wchow@coh.org
Adaptimmune Cancer - Sarcoma A Pilot Study of Genetically Engineered NY-ESO-1 Specific (c259) T Cells in HLA-A2+ Patients With Synovial Sarcoma Active, not recruiting
City of Hope
Mihaela Cristea, MD
(626) 256-4673 x89200
mcristea@coh.org
Adaptimmune Cancer - Ovarian A Phase I/IIa, Open Label Clinical Trial Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs Specific for NY-ESO-1 in Patients With Recurrent or Treatment Refractory Ovarian Cancer. Recruiting
City of Hope
Karen Reckamp, MD
(626) 256-4673 x89200
kreckamp@coh.org
Adaptimmune Cancer - Lung Screening Protocol for Tumor Antigen Expression and HLA Sub-Type in NSCLC Recruiting
City of Hope
Karen Reckamp, MD
(626) 256-4673 x89200
kreckamp@coh.org
Adaptimmune Cancer - Lung A Phase I/II Open Label Clinical Trial Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs Specific for NY-ESO-1 in Subjects With Stage IIIb or Stage IV Non-Small Cell Lung Cancer (NSCLC) Recruiting
City of Hope
Karen Reckamp, MD
(626) 256-4673 x89200
kreckamp@coh.org
Adaptimmune Cancer - Lung A Phase I/ II Dose Escalation Open Label Clinical Trial Evaluating the Safety and Efficacy of MAGE A10ᶜ⁷⁹⁶T in Subjects With Stage IIIb or Stage IV Non-Small Cell Lung Cancer (NSCLC) Active, not recruiting
UCSD Aivita Ovarian and Fallopian Tube Carcinoma Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Advanced Epithelial Ovarian Carcinomas Active, not recruiting
UCI & UCSD & UC Davis
UCI Stem Cell Clinic
949-824-3990
stemcell@uci.edu

Jane McCluskey
916-703-9302
jmccluskey@ucdavis.edu
Aivita Biomedical Cancer - Brain Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Newly Diagnosed Glioblastoma Active, not recruiting
UCSF
Gabrielle Garcia
Gabriel.Garcia@ucsf.edu
Allo Vir, Inc. BK Viremia in Kidney Transplant Recipients Phase 2 study in patients with BK Viremia in Kidney Transplant Recipients Recruiting
UC Davis
Jane McCluskey
916-703-9302
jmccluskey@ucdavis.edu
AlloVir Kidney transplant Phase 2 multicenter, randomized, double-blind, placebo-controlled, multiple dosing interval, 3-period study of the safety, tolerability and effectiveness of adoptively transferred Viralym-M multivirus-specific T cells in kidney transplant recipients with Recruiting
City of Hope
Rie Miyahira
626-256-4673 ext 80032
rmiyahira@coh.org
Angiocrine Bioscience Cancer - Leukemia A Phase 1B, Open Label, Multi-Center Trial of AB-110 in Adults With Hematologic Malignancies Undergoing Cord Blood Transplantation Recruiting
UCSD Asterias Biotherapeutics Spinal Cord Injury Dose Escalation Study of AST-OPC1 in Spinal Cord Injury No longer active
UC Davis
Jane McCluskey
916-703-9302
jmccluskey@ucdavis.edu
Atara Bio Hematologic Malignancies An Open-label, Single-arm, Multicohort, Phase 2 Study to Assess the Efficacy and Safety of Tabelecleucel in Subjects with Epstein-Barr Virus-associated Diseases Recruiting
City of Hope
Erminia Massarelli, MD
626-218-9200
emassarelli@coh.org
Atara Bio. Cancer - Nasopharyngeal Carcinoma Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC) No longer active
UC Davis
Jane McCluskey
916-703-9302
jmccluskey@ucdavis.edu
Atara Bio. EBV-PTLD Multicenter, Open Label, Phase 3 Study of Tabelecleucel for Solid Organ Transplant Subjects with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure of Rituximab or Rituximab and Chemotherapy (ALLELE Study) No longer active
UC Davis
Jane McCluskey
916-703-9302
jmccluskey@ucdavis.edu
Autolus Acute Lymphoblastic Leukaemia An Open-Label, Multi-Centre, Phase Ib/II Study Evaluating the Safety and Efficacy of AUTO1, a CAR T Cell Treatment Targeting CD19, in Adult Patients with Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia Recruiting
UCSF and UC Davis
Julie DeCaris
510-428-3885. ext.2739
Julie.decaris@ucsf.edu

Jane McCluskey
916-703-9302
jmccluskey@ucdavis.edu
Bioverativ Therapeutics, Inc Sickle Cell Disease A Phase 1/2, Open-Label, Multicenter, Single-Arm Study to Assess the Safety, Tolerability, and Efficacy of BIVV003 for Autologous Hematopoietic Stem Cell Transplantation in Patients with Severe Sickle Cell Disease Recruiting
UCSF
Cyrus Bascon
510-428-3885 ext 5396
CBascon@mail.cho.org
bluebird bio Sickle Cell Disease A Study Evaluating the Safety and Efficacy of the LentiGlobin BB305 Drug Product in Severe Sickle Cell Disease Active, not recruiting
UCI
Breana Chew
949-824-8116
chewbc@hs.uci.edu
Brain Neurotherapy Bio Parkinson's Open-Label Safety Study of Glial Cell Line-Derived Neurotrophic Factor Gene Transfer (AAV2- GDNF) in Parkinson’s Disease Recruiting
UCI
UCI Stem Cell Clinic
(949) 824-3990
stemcell@uci.edu
BrainStorm Cell Therapeutics Amyotrophic Lateral Sclerosis (ALS) A phase 3, randomized, double-blind, placebo-controlled multicenter study to evaluate efficacy and safety of repeated administrations of NurOwn® (autologous mesenchymal stem cells secreting neurotrophic factors) in participants with ALS Recruiting
UC Davis
Jane McCluskey
916-703-9302
jmccluskey@ucdavis.edu
Cabaletta Pemphigus Vulgaris Phase 1, Open-label, Safety and Dosing Study of Autologous Desmoglein 3 Chimeric Autoantibody Receptor T Cells (DSG3-CAART) in Subjects with Active, Anti-DSG3, Mucosal-dominant Pemphigus Vulgaris Recruiting
UCSD Calibr Relapsed/Refractory B-cell Lymphomas Long term follow-up study for patients administered CLBR001 , a CAR-T cell Recruiting
UCSD Calibr Relapsed/Refractory B-cell Lymphomas CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies Recruiting
UCLA
Maricela Gonzalez
(310) 557-3729
mmgonzalez@mednet.ucla.edu
Calimmune HIV/AIDS Safety Study of a Dual Anti-HIV Gene Transfer Construct to Treat HIV-1 Infection No longer active
UC Davis
Jane McCluskey
916-703-9302
jmccluskey@hotmail.com
Capricor Therapeutics COVID A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Intravenous Delivery of CAP-1002 in Patients with Severe COVID-19 No longer active
UC Davis
Jane McCluskey
916-703-9302
jmccluskey@ucdavis.edu
Capricor Therapeutics Duchenne Muscular Dystrophy Open-Lael Extension of the HOPE-2 Duchenne Muscular Dystrophy Trial (HOPE-2-OLE) Recruiting
UC Davis
Jane McCluskey
916-703-9302
jmccluskey@ucdavis.edu
Capricor Therapeutics Muscle - Duchenne Muscular Dystrophy A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy (HOPE-2) No longer active
UCI
Julia Kimberly Fong
juliakf@hs.uci.edu
Cartesian Therapeutics MYASTHENIA GRAVIS (MG) Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG) Recruiting
UCSF
Rebecca Hoh
415.476.4082 ext. 139
Rebecca.Hoh@ucsf.edu
Case Western Reserve University HIV A Comparative Study of Autologous CD4+ T Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases SB-728 versus ex vivo Expanded Unmodified Autologous CD4+ T Cells in Treated HIV-1 Infected Subjects (TRAILBLAZER) Recruiting
City of Hope
Hormoz Babaei Mirshkarlo
626-218-8074
hmirshkarlo@coh.org
Celgene Cancer - Lymphoma An Exploratory Phase 1/2 Trial to Evaluate the Safety and Efficacy of JCAR017 Combinations in Subjects with Relapsed/Refractory B-Cell Malignancies (PLATFORM) Recruiting
UCSF
Joseph Seo
415-514-4805
Joseph.Seo@ucsf.edu
Cellectis, SA Multiple Myeloma Phase I, open label dose‐escalation study to evaluate the safety, expansion, persistence and clinical activity of UCARTCS1A (allogeneic engineered T‐cells expressing anti‐CS1 chimeric antigen receptor), administered in patients with Relapsed/Refractory Mu Recruiting
UCI & UC Davis
UCI: Jennifer Scott
714-456-4956
scottj2@uci.edu

UC Davis: Kate Trigg
916-734-8033
ktrigg@ucdavis.edu
Celularity, Inc. Hospitalized COVID-19 patients A Phase I/II Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK-001) for the Treatment of Adults With COVID-19 Recruiting
City of Hope
Cheryl De Guzman
626-218-5613
CDeGuzman@coh.org
Children’s Hospital Los Angeles Infection After Stem Cell Transplant Antiviral Cellular Therapy for Enhancing T-cell Reconstitution Recruiting
UCSF & UCSD & CIRM
Jane McCluskey
916-703-9302
jmccluskey@ucdavis.edu
CIRM ARDS/COVID Prospective, Randomized, Multi-center Phase 2 Clinical Trial of Allogeneic Bone Marrow-derived Human Mesenchymal Stromal Cells (hMSCs) for the Treatment of Acute Respiratory Distress Syndrome (ARDS) Recruiting
UCSF
Cyrus Bascon
510-428-3885 ext 6953
Cyrus.bascon@ucsf.edu
CIRM & NHLBI Severe sickle cell disease Transplantation of CRISPRCas9 Corrected Hematopoietic Stem Cells (CRISPR_SCD001) in Patients With Severe Sickle Cell Disease Recruiting
City of Hope
Tanya Dorff, MD
626-218-9200
tdorff@coh.org
City of Hope Cancer - Prostate PSCA-CAR T Cells in Treating Patients With Metastatic Castration Resistant Prostate Cancer Recruiting
City of Hope
Elizabeth Budde, MD, PhD
626-218-2405
ebudde@coh.org
City of Hope Cancer - Lymphoma Angiocrine: HuVEC infusion post HCT in lymphoma (Budde) Recruiting
City of Hope
Fatemeh Bidmeshki
626-218-9393
fbidmeshki@coh.org
City of Hope Cancer - Brain HER2-CAR T Cells in Treating Participants With Brain or Leptomeningeal Metastases Recruiting
City of Hope
Joseph Rosenthal, MD
626-256-4673 ext 88442
jrosenthal@coh.org
City of Hope Sickle Cell Disease Safety of Blood Stem Cell Mobilization With Plerixafor in Patients With Sickle Cell Disease (PISMO) Recruiting
City of Hope
Behnam Badie, MD;
626-256-4673
bbadie@coh.org
City of Hope Cancer - Brain Memory-Enriched T Cells in Treating Patients With Recurrent or Refractory Grade III-IV Glioma Recruiting
City of Hope
Lucy Ghoda
626-218-3605
lghoda@coh.org
City of Hope Neurodegenerative Disorder Acquisition of Skin Biopsy Samples from Healthy Volunteers and Patients Diagnosed with X-Linked Adrenoleukodystrophy (ALD), Canavan Disease (CD) and other Inherited Leukodystrophies Recruiting
City of Hope
Teresa Kim
626-218-0263
teresakim@coh.org
City of Hope Sickle Cell Disease A Pilot Study to Evaluate the Safety and Feasibility of Induction of Mixed Chimerism in Sickle Cell Disease Patients with COH-MC-17: a Non-Myeloablative, Conditioning Regimen and CD4+ T-cell-depleted Haploidentical Hematopoietic Transplant Recruiting
City of Hope
L. Elizabeth Budde, MD, PhD
(626) 256-4673
ebudde@coh.org
City of Hope Cancer - Leukemia Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Recruiting
City of Hope
Behnam Badie, MD
(626) 256-4673 ext 60098
bbadie@coh.org
City of Hope Cancer - Brain Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma Recruiting
City of Hope
Amrita Krishnan, MD
(626) 256-4673 ext 62405
AKrishnan@coh.org
City of Hope Cancer - Lymphoma (AIDS-Related) Gene Therapy After Frontline Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma Active, not recruiting
City of Hope
Jana Portnow, MD
(626) 256-4673 ext 62909
jportnow@coh.org
City of Hope Cancer - Brain Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas Recruiting
City of Hope
Jana Portnow, MD
(626) 256-4673 ext 62909
jportnow@coh.org
City of Hope Cancer - Brain Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas Active, not recruiting
City of Hope & UCLA
City of Hope: Amrita Krishnan, MD
(626) 256-4673 ext 62405
AKrishnan@coh.org

UCLA: Maricella Gonzalez
310-557-3729
mmgonzalez@mednet.ucla.edu
City of Hope HIV/AIDS Safety Study of Zinc Finger Nuclease CCR5-modified Hematopoietic Stem/Progenitor Cells in HIV-1 Infected Patients Recruiting
UCSF
Allegra Koch
415-476-2381
Allegra.koch@ucsf.edu
CRISPR Therapeutics B Cell Malignancies Non-hodgkin Lymphoma, B-cell Lymphoma, Adult B Cell ALL A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD19 Allogeneic CRISPR-Cas9–Engineered T Cells (CTX110) in Subjects With Relapsed or Refractory B Cell Malignancies Recruiting
1 2 3

Clinical trials conducted at CIRM Alpha Stem Cell Clinics must comply with applicable federal and state laws and medical and ethical standards governing the conduct of human clinical trials. If you or a family member is interested in participating in a clinical trial, please visit clinicaltrials.gov to find a trial near you.

Find Out More:
About Alpha Stem Cell Clinics
Alpha Clinics News